Prism Medico & Pharmacy Reports Strong FY26 Turnaround, Posts Profit

FY26 Net Profit: ₹0.32 crore | FY25 Net Loss: ₹0.05 crore
FY26 Revenue: ₹2.44 crore | FY25 Revenue: ₹0.63 crore

Reader Takeaway: Turnaround to profitability and strong revenue growth offset by inoperative bank accounts and auditor changes.

What just happened

Prism Medico and Pharmacy Ltd announced its audited standalone financial results for the fiscal year ended March 31, 2026. The company has successfully transitioned from a net loss of ₹0.05 crore in FY 2025 to a net profit of ₹0.32 crore in FY 2026. Revenue from operations also saw a substantial jump, rising to ₹2.44 crore from ₹0.63 crore in the previous fiscal year.

The company's statutory auditors issued an unmodified opinion on the financial statements for FY 2026, indicating that the financial reporting is free from material misstatement.

Why this matters

This marks a significant financial turnaround for Prism Medico and Pharmacy, demonstrating its ability to generate profits after a period of loss. The tripling of revenue indicates a strong improvement in business performance and market traction. The unmodified auditor's opinion provides an added layer of assurance to investors regarding the accuracy of the reported financial numbers.

The backstory

In the previous fiscal year, FY 2025, Prism Medico and Pharmacy had reported a net loss of ₹0.05 crore on revenues of ₹0.63 crore. The current results show a decisive shift towards profitability and significant top-line growth.

What changes now

Investors can see a positive financial trajectory for the company in FY26. The turnaround in profitability and revenue growth are key performance indicators that may influence investor sentiment and stock performance. However, certain operational concerns flagged in the report require attention.

Risks to watch

Two key points require investor attention:

• Inoperative Bank Accounts: Three bank accounts—with ICICI Bank (Mumbai), Union Bank of India, and Canara Bank—were reported as inoperative as of March 31, 2026. The operational status of these accounts could impact the company's financial management and transaction capabilities.
• Auditor Resignation: The company noted the resignation of its outgoing statutory auditor during the fiscal year. While the current audit has an unmodified opinion, the change in auditors might warrant monitoring for continuity in governance and financial oversight.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue: ₹2.44 crore in FY 2026, up from ₹0.63 crore in FY 2025.
• Net Profit/(Loss): ₹0.32 crore profit in FY 2026, compared to a ₹0.05 crore loss in FY 2025.
• Audit Opinion: Unmodified opinion for FY 2026.
• Bank Accounts: Three accounts reported as inoperative as of March 31, 2026.
• Auditor: Resignation of outgoing statutory auditor noted.

What to track next

Investors should track the company's progress in resolving the inoperative bank accounts issue and how the auditor transition impacts financial reporting and governance in the upcoming periods. Continued revenue growth and profitability will be crucial.